InfuSystem Holdings, Inc. (NYSE:INFU) Given Consensus Recommendation of "Buy" by Analysts

Key Points

• InfuSystem Holdings, Inc. (NYSE:INFU) has received a consensus rating of "Buy" from five research firms, with an average 1-year price target of $13.50.
• Notable recent coverage includes a $12.00 price target from Roth Capital and a $15.00 target from Lake Street Capital, despite Zacks Research downgrading the stock from "strong-buy" to "hold."
• Institutional investors have significantly increased their stakes in InfuSystem, with CWM LLC boosting its holdings by 1,160.1% in the second quarter, showcasing strong institutional interest.

Shares of InfuSystem Holdings, Inc. (NYSE:INFU - Get Free Report) have been given a consensus rating of "Buy" by the five research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, one has given a buy rating and three have assigned a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $13.50.

INFU has been the topic of several recent research reports. Roth Capital initiated coverage on InfuSystem in a research note on Tuesday, July 22nd. They issued a "buy" rating and a $12.00 price target on the stock. Lake Street Capital initiated coverage on InfuSystem in a research note on Monday, September 22nd. They issued a "buy" rating and a $15.00 price target on the stock. Finally, Zacks Research cut InfuSystem from a "strong-buy" rating to a "hold" rating in a research note on Monday.

InfuSystem Price Performance

Shares of INFU stock opened at $10.17 on Wednesday. The stock has a market cap of $207.73 million, a price-to-earnings ratio of 169.53 and a beta of 1.79. The business's fifty day moving average is $9.52 and its 200 day moving average is $6.97. InfuSystem has a twelve month low of $4.61 and a twelve month high of $11.04. The company has a quick ratio of 1.59, a current ratio of 1.98 and a debt-to-equity ratio of 0.50.

Insider Buying and Selling

In other InfuSystem news, Director Scott Shuda sold 5,752 shares of the business's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $9.67, for a total value of $55,621.84. Following the sale, the director directly owned 94,000 shares of the company's stock, valued at approximately $908,980. The trade was a 5.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 11.40% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. CWM LLC lifted its holdings in shares of InfuSystem by 1,160.1% during the second quarter. CWM LLC now owns 4,826 shares of the company's stock valued at $30,000 after purchasing an additional 4,443 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of InfuSystem during the second quarter valued at $33,000. Jump Financial LLC bought a new position in shares of InfuSystem during the first quarter valued at $58,000. Williams & Novak LLC bought a new position in shares of InfuSystem during the second quarter valued at $77,000. Finally, Virtu Financial LLC bought a new position in shares of InfuSystem during the first quarter valued at $86,000. 71.13% of the stock is owned by institutional investors.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.